Skip to main content

Advertisement

Table 2 EGFR Gene mutation status

From: Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Exons Mutation type Frequency No. (%)a
Erlotinib Group Gefinitib Group
18 G719Ab 1 (0.9%) 2 (1.2%)
G719S 0 (0) 1 (0.6%)
G719C 1(0.9%) 1 (0.6%)
19c Del 43 (39.8%) 84 (49.1%)
Delins 6 (5.6%) 13 (7.6%)
20 T790M 0 (0) 0 (0)
S768I 0 (0) 0 (0)
21d L858R 47 (43.5%) 59 (34.5%)
L861Q 10 (9.3%) 13 (7.6%)
  1. Abbreviations: del stands for deletion; delins stands for deletion-insertion
  2. a Two patients had double mutation
  3. b One patient had G719A and 19 del; one patient had G719A and L858R
  4. c Mutation of exon 21 in Erlotinib Group and Gefinitib Group (45.4% vs 56.7%, P = 0.067)
  5. d Mutation of exon 19 in Erlotinib Group and Gefinitib Group (52.8% vs 42.1%, P = 0.086)